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Platelet activation plays a key role in normal haemostasis and pathological thrombosis. Platelet activation
is rapid; within minutes of stimulation, platelets generate bioactive phospholipids, secrete their granule
contents, activate integrins and aggregate together to form a haemostatic plug. These events are
dependent on ATP synthesis. Mitochondrial function in platelets from healthy volunteers and patients
with a range of diseases indicate an important role for oxygen consumption in oxidative phosphorylation
in normal and pathological function. Platelets also consume oxygen during oxidation reactions, such as
cyclooxygenase-dependent thromboxane A2 synthesis. In this study, we used high-resolution respi-
rometry to investigate rapid changes in oxygen consumption during platelet activation. We demon-
strated a rapid, transient increase in oxygen consumption rate within minutes of platelet stimulation by
the physiological activator, thrombin. This was partly inhibited by aspirin and by oligomycin. This shows
that high resolution respirometry can provide information regarding rapid and dynamic changes in
oxygen consumption during platelet activation.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Platelet activation is central to haemostasis and arterial
thrombosis [1]. Platelets adhere at sites of vascular injury, generate
and release bioactive phospholipids, release their granule contents
through exocytosis, and activate their major integrin, aIIbb3. These
events lead to recruitment of further platelets and platelet aggre-
gation, forming a haemostatic plug or occlusive thrombus [1].
Platelet activation requires ATP, which is provided by increased
mitochondrial oxidative phosphorylation (OXPHOS) and glycolysis
[2e5]. Pioneering experiments starting in the 1970s using Clark-
type oxygen electrodes showed that platelet activation with a
range of physiological stimuli triggers a rapid increase in O2 con-
sumption, attributed to increased mitochondrial OXPHOS (inhibi-
ted by oligomycin) and oxidation of arachidonic acid by
cyclooxygenase (COX; inhibited by aspirin) [6,7]. However, Clark-
type electrodes show a number of problems, including uniformgy, Tennis Court Road, Cam-
r Inc. This is an open access articlesignal drift, changes in sensor response, and bubble formation on
the electrode [8]. Importantly, the resolution achievable with Clark-
type electrodes is relatively low compared to high-resolution ap-
proaches currently available.
More recent methodologies for studying O2 consumption, such
as the Oxygraph-2k high-resolution respirometer (Oroboros In-
struments) and the high-throughput Seahorse Extracellular Flux
(XF) Analyzer (Seahorse Bioscience Inc.), have stimulated renewed
interest in the regulation of O2 consumption in many primary cell
types. Each system has its own advantages and disadvantages
[compared in detail in Ref. [9]]. The Seahorse XF has been used to
characterise platelet O2 consumption, mitochondrial function and
glycolysis. This has usually been studied in unstimulated platelets,
either fromhealthy donors [9e11], or frompatients with conditions
such as sickle cell disease [12], pulmonary hypertension [13], type 2
diabetes [14] or preeclampsia [15]. A small number of studies have
reported changes in platelets following stimulation with thrombin,
which increased O2 consumption rate by approximately 25% at the
nextmeasured time (approximately 8min later) [3,16]. By this time,
many of the rapid platelet functional responses have already
occurred, including granule secretion and integrin activation [17].
Platelet O2 consumption andmitochondrial function have also beenunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ration in unstimulated platelets from healthy donors [18], patients
with sepsis [19] or Alzheimer's disease [20], and in response to drug
treatment [21,22] or high-intensity training [23]. However, we are
not aware of any studies that report the kinetics of rapid changes in
O2 consumption using the Oxygraph-2k system in response to
platelet stimulationwith physiological activators such as thrombin.
In this study, we used the Oxygraph-2k to investigate changes in
platelet O2 consumption following stimulation by thrombin. We
describe a rapid, transient increase in O2 consumption rate that is
partly dependent on COX activity and OXPHOS, but also depends on
other pathways. This shows that high-resolution respirometry can
provide information regarding rapid and dynamic changes in O2
consumption during platelet activation.
2. Methods
2.1. Materials
All reagents were purchased from Sigma unless otherwise
specified. Amidated peptides, SFLLRN-NH2 and AYPGKF-NH2, were
from Bachem (Weil am Rhein, Germany).
2.2. Washed platelet preparation
Blood was drawn by venepuncture into sodium citrate-
containing vacutainers (3.8% v/v) from healthy, drug-free volun-
teers, who had givenwritten, informed consent in accordance with
the Declaration of Helsinki. Use of human blood from healthy vol-
unteers was approved by the Human Biology Research Ethics
Committee, University of Cambridge. Acid citrate dextrose (85mM
tri-sodium citrate, 71mM citric acid, 111mM D-glucose) was added
(1:7 v/v) and platelet-rich plasma (PRP) separated by centrifugation
(200 g, 10min, room temp., no brake). Prostaglandin E1 (100 nM;
Cambridge Bioscience) and apyrase (Grade VII; 0.02 U/ml) were
added to PRP to prevent platelet activation during preparation.
Platelets were pelleted from PRP by centrifugation (600 g, 10min,
room temp., with brake) and resuspended at a density of 1 108
platelets/ml in HEPES-buffered saline (HBS; 135mM NaCl, 10mM
HEPES, 3mM KCl, 1mM MgCl2, 0.34mM NaH2PO4, pH 7.4, sup-
plemented with 0.9mg/ml D-glucose). Platelets were rested at
30 C for 30min prior to experimentation. For inhibition of COX,
platelets were incubated with aspirin (300 mM) 30min prior to
being added to the Oxygraph chamber. Control samples were
incubated with an equivalent amount of the vehicle (DMSO) for the
same time. In contrast, oligomycin (or its vehicle, ethanol, as con-
trol) were added directly to platelets in the Oxygraph chamber, as
indicated in the Results section.
2.3. Measurement of oxygen flux during platelet activation
Oxygen consumption in washed human platelets was measured
using an Oxygraph-2k high-resolution respirometer (Oroboros In-
strument, Innsbruck, Austria) in 2ml glass chambers at a constant
temperature of 37 C and stirrer speed 750 rpm. Oxygen flux (JO2),
which is directly proportional to oxygen consumption rate, was
continuously recorded with a 2 s sampling rate using DatLab soft-
ware 6.1 (Oroboros Instruments, Austria). Calibration at air satu-
ration was carried out every day prior to experimentation, and all
data were corrected for background instrumental oxygen flux in
accordance to themanufacturer's instructions. Platelets (1 108/ml
in HBS with glucose, as described above) were added to the Oxy-
graph chambers and allowed to reach a stable baseline oxygen
consumption rate prior to stimulation in the presence of CaCl2
(2mM). All reagents injected into the chambers (CaCl2, thrombin,PAR agonists, oligomycin or vehicle control) were warmed to room
temperature prior to addition.
2.4. Statistical analyses
Data are reported as mean± standard error of the mean (SEM);
the reported n value indicates the number of independent platelet
preparations from different donors. Datawere analysed by paired t-
test for comparison of two conditions, and by RM two-way ANOVA
with Sidak multiple comparison test for comparison of the effect of
oligomycin in the absence or presence of aspirin.
3. Results
3.1. Thrombin triggers a rapid increase in oxygen flux in platelets
Washed platelets were treated with DMSO (0.1%; the vehicle
control for aspirin e see next section) then stimulated with the
physiological activator, thrombin (1 U/ml) in the presence of
extracellular CaCl2 (2mM). Extracellular oxygen concentration was
monitored. This was converted to the oxygen flux, JO2, which is
directly proportional to O2 consumption rate, and is shown in
Fig. 1AeB. Prior to stimulation, JO2 was 8.5± 0.4 pmol s1 108
platelets. Thrombin triggered a rapid, transient increase in JO2. The
peak increase in JO2 was 39.6± 5.6 pmol s1 108 platelets higher
than the pre-stimulation baseline (Fig.1C; a 5.4± 0.6 -fold increase)
and occurred at 72.8± 2.9 s after stimulation (Fig. 1D). JO2 then
decreased over the following 20min. A previous study using the
Seahorse XF [3] reported that thrombin stimulated an increase in
oxygen consumption rate by ‘approximately 25%’ at the next re-
ported point of measurement (8min later). For comparison, in our
experiments, after 10min stimulation with thrombin, JO2 was
38.3± 13.0% higher than the pre-stimulation baseline (Fig. 1E;
n¼ 5; p¼ 0.045).
3.2. COX activity contributes to the rapid increase in JO2
COX enzymes use oxygen in the generation of eicosanoids from
arachidonic acid [24]. Arachidonic acid (500 mM) stimulated a rapid
increase in JO2, which was inhibited by aspirin, a COX inhibitor
(300 mM; Suppl. Fig. 1). To assess the contribution of COX to the
thrombin-triggered increase in JO2, platelets were stimulated in the
presence of aspirin (Fig. 1A, right hand panel). The peak increase in
JO2 was significantly inhibited and delayed by aspirin (Fig. 1CeD).
(The delay in reaching peak JO2 is clearly shown in the inset panel of
Fig. 1B.) However, thrombin was still able to trigger an increase in
JO2 that was 2.4± 0.3 -fold higher than the pre-stimulation base-
line, indicating that thrombin also rapidly activates other sources of
O2 consumption.
In contrast to the peak increase in JO2, the increased JO2 10min
after stimulation was not significantly affected by aspirin (Fig. 1E;
p¼ 0.93; n¼ 5).
3.3. Protease-activated receptor agonists rapidly increase JO2
In human platelets, thrombin activates the protease-activated
receptors, PAR1 and PAR4, and glycoprotein Ib (GPIb). It has been
reported that thrombin-stimulated O2 consumption is dependent
on GPIb, and that stimulation of PAR1 does not increase O2 con-
sumption [25]. However, we observed a rapid and transient in-
crease in JO2 when platelets were stimulated with SFLLRN-NH2
(10 mM) or AYPGKF-NH2 (200 mM), selective agonists of PAR1 and
PAR4, respectively (Fig. 2AeB). Under these conditions, aspirin
significantly inhibited the peak increase in JO2 in response to
SFLLRN-NH2, from 16.9± 5.9 to 6.9± 0.7 pmol s1 108 platelets
Fig. 1. Thrombin triggers a rapid increase in oxygen flux (JO2), which is partly inhibited by aspirin.
Washed platelets were treated with aspirin (300 mM) or its vehicle (DMSO, 0.1%; ‘control’) then stimulated with thrombin in an Oxygraph-2k high resolution respirometer. CaCl2
(final concentration, 2mM) was added at the black arrowhead (‘C’). Thrombin (1 U/ml) was added at the white arrowhead (‘T’). In A, individual traces from platelet independent
platelet preparations (different donors) are shown. The control (DMSO) is the left-hand panel, and aspirin-treated platelets are shown in the right-hand panel. Matched colours
indicate the pair experiments. The mean signal (n¼ 5) is shown in B; the dashed region is expanded in the right-hand panel. The peak change in JO2 (above the baseline prior to
thrombin addition) is shown in C and the time from thrombin addition to this peak is shown in D (mean þ SEM; n ¼ 5; **p < 0.01 for control vs. aspirin). The JO2 10min after
thrombin addition is shown in E, reported as fold change over the baseline (n.s. not significant for control vs. aspirin; yp< 0.05 for fold-change at 10min significantly different to
pre-stimulation baseline). This measure was chosen to aid comparison with a previous report, as described in the Results section.
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were stimulated with AYPGKF-NH2 (the peak increase in JO2 was
11.3± 2.7 pmol s1 108 platelets in the absence of aspirin, and
7.9± 1.3 pmol s1 108 platelets in aspirin-treated platelets; n¼ 5;
p¼ 0.22). These data are summarised in Fig. 2BeD. 10min after
stimulation with SFLLRN-NH2, JO2 was 14.5± 3.9% above the pre-
stimulation baseline (n¼ 5; p< 0.05), whereas 10min after
AYPGKF-NH2, JO2 was 16.0± 7.1% (n¼ 5; p¼ 0.85) above the pre-
stimulation baseline.
3.4. The higher post-stimulation JO2 is inhibited by oligomycin
To determine the contribution of OXPHOS to the thrombin-
stimulated changes in JO2, we treated platelets with oligomycin
(2.5 mM), an inhibitor of the mitochondrial F1Fo-ATP synthase.Oligomycin rapidly decreased baseline JO2 (Fig. 3AeB; p¼ 0.011
compared with vehicle control). The peak increase in JO2 was also
partially inhibited by oligomycin, either in the absence or presence
of aspirin (Fig. 3A and C). The increase in JO2 10min after stimu-
lation was inhibited by oligomycin in the presence of aspirin
(Fig. 3D). By 20min post-stimulation, aspirin had no effect and
oligomycin completely inhibited the remaining increase in JO2
(note that this is relative to an already-inhibited baseline). This
indicates that oligomycin-sensitive OXPHOS contributes to the
rapid, transient increase in JO2, and to the sustained smaller in-
crease. Notably, other sources of O2 consumption also contribute to
the peak change in JO2, as the rapid increase in oxygen consump-
tion was not completely inhibited by aspirin and oligomycin in
combination.
Fig. 2. Protease-activated receptor agonist peptides trigger a rapid increase in JO2.
Washed platelets, treated with aspirin or vehicle control as in Fig. 1, were stimulated with SFLLRN-NH2, a PAR1 agonist (A) or AYPGKF-NH2, a PAR4 agonist (B). The traces represent
the mean signal (n¼ 5). The black arrowhead indicates addition of CaCl2. The white arrowhead indicates addition of agonist peptide. The dashed area is shown expanded as an inset
panel to the right. The peak change in JO2 (above the baseline prior to thrombin addition) is shown in C and the time from agonist peptide addition to this peak is shown in D
(mean þ SEM; n ¼ 5; ***p < 0.001 for control vs. aspirin, n.s. not significant; n ¼ 5).
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Platelet stimulation with thrombin triggers a rapid, transient
increase in JO2. The peak of this increase occurred slightly later than
1min after stimulation and then declined to a new baseline over
the following 10e20min. The rapid increase in JO2 occurs on the
same timescale as more-commonly measured platelet functions,
such as aggregation or granule secretion and shows striking simi-
larities to thrombin-triggered intracellular Ca2þ signalling [e.g.
Ref. [26]]. In contrast, published reports of platelet O2 consumption
using the Seahorse XF have so far missed this rapid increase in JO2
[3]. Extracellular flux analysis has shown a relatively small increase
in oxygen consumption rate (OCR) of around 25%. This is similar in
magnitude to the approximately 38% average increase in JO2 that
we observed 10min after stimulation, after most of the peak in-
crease in JO2 had subsided. This suggests that although thepublished methods using Extracellular Flux Analysis may be useful
for investigatingmore sustained changes in oxygen consumption in
platelets following stimulation, high resolution respirometry is
more useful for investigating the rapid, transient burst of O2 con-
sumption that occurs immediately following platelet stimulation.
In this study, the platelets were isolated from plasma and
resuspended in HEPES-buffered saline with 5mM glucose as the
exogenous source of metabolic substrates. This is a relatively
common approach for many platelet signalling studies [27], and an
advantage of this approach is that data can be readily compared
with published data on platelet aggregation, granule secretion and
intracellular signalling. However, the effect of adding other exog-
enous substrates, such as glutamine, pyruvate or fatty acids, could
be investigated in this protocol, and may affect the extent of in-
crease in OXPHOS following stimulation [3].
The rapid increase in JO2 in response to thrombin was also
Fig. 3. Oligomycin inhibits JO2 in unstimulated and stimulated platelets.
Washed platelets were treated with oligomycin (2.5 mM) or its vehicle (ethanol, 0.05%) as control at the point indicated by the double black arrowhead (‘O’). CaCl2 was then added
(black arrowhead, ‘C’) followed by thrombin (white arrowhead, ‘T’). The traces showmean signal (n¼ 5) from platelets with either DMSO (0.1%; left-hand panel) or aspirin (300 mM;
right-hand panel). The immediately decrease in JO2 following addition of oligomycin is shown in C (mean þ SEM; n ¼ 5; **p < 0.01). The mean peak increase in JO2 above baseline
prior to thrombin addition (but after oligomycin or its control) is shown in D (mean þ SEM; n ¼ 5; *p < 0.05 for control vs. ethanol). The increases in JO2 10 or 20min after thrombin
addition are shown in D or E, respectively.
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PAR1 or PAR4. This is not very surprising, since thrombin triggers
intracellular signalling in platelets by activating these receptors
[28]. The increase in JO2 10min after stimulation was statistically
significant for PAR1 stimulation, though this was relatively small,
and may not be robustly observed under different experimental
conditions. This may explain why a previous report found no in-
crease in OXPHOS in response to PAR1 stimulation [25].
The pioneering studies of the 1970s onwards attributed the
rapid increase in O2 consumption rate to COX activity [6,7].
Although we broadly replicated these observations in this study,our high-resolution respirometry shows a more complex picture. In
our study, aspirin significantly inhibited the rapid, peak increase in
JO2, consistent with the previous reports. However, with high res-
olution respirometry, we observe that there is still a substantial
increase in JO2, indicating that there are other mechanisms of O2
consumption occurring. This demonstrates the benefit of high-
resolution respirometry over Clark-type electrodes in understand-
ing the changes in O2 consumption during platelet activation.
Similarly, in the early studies, oligomycin-sensitive OXPHOS
accounted for the basal O2 consumption in unstimulated platelets
but did not significantly contribute to the increased O2
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strate that the baseline O2 consumption could be inhibited by oli-
gomycin and likely represents the contribution of OXPHOS to ATP
synthesis in unstimulated platelets. However, we also show that
oligomycin inhibits the rapid peak increase in JO2, independently of
COX activity. This might represent a rapid, transient activation of
OXPHOS, which might support ATP-dependent events during the
earliest stages of platelet activation. It could also represent another
pathway of O2 consumption that is reduced by the inhibition of
baseline ATP synthesis. The remaining O2 consumption, which is
not inhibited by aspirin or oligomycin, could involve other O2
consuming pathways that are known to be activated in platelets,
such as 12-lipoxygenase, xanthine oxidase or NADPH oxidase
[29e32].
In summary, we show that high-resolution respirometry can be
used to investigate the kinetics of changes in O2 consumption rate
in stimulated platelets, across a timescale that is relevant to the
rapid activation of platelets. Our data show that OXPHOS is a major
contributor to O2 consumption in unstimulated platelets. Following
stimulation, O2 is rapidly consumed in a COX-dependentmanner, as
previously reported. However, the high resolution of this approach
shows that other pathways of O2 consumption are also rapidly
activated. This gives a more complex picture of the rapid kinetics of
changes in O2 consumption thanwas possible with Clark electrodes
or has been reported with Extracellular Flux Analysis. High reso-
lution respirometry is therefore a useful tool to investigate the
rapid kinetics of changes in O2 consumption during platelet
activation.
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